A Phase 3 interventional study of teplizumab and Placebo in Type 1 Diabetes Mellitus, sponsored by Provention Bio, Inc.. Completed at 62 sites in 9 countries. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-04-24.
Sponsored by Provention Bio, Inc. (part of Sanofi) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 3 in phase 3, and was the 6th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
Abdullah Kars · Sites in Turkey
Ages 18–45
By country, each count listing its studies:
teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 8 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 4 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2019.
This study's enrollment of 328 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 60 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Provention Bio, Inc., one of the names counted as Sanofi. Under that name alone:
Provention Bio, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 10 under way, 1 of them phase 3. Of 56 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 14th largest by enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2019, is one of 20 in phase 3, and was the 51st registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, from their registry updates:
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..
Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, multi-center study to evaluate the efficacy and safety of teplizumab, a humanized, anti-CD3 monoclonal antibody, in children and adolescents ages 8 through 17 recently diagnosed with type 1 diabetes (within 6 weeks of diagnosis). Approximately 300 participants will be randomized at a ratio of 2:1 to either the teplizumab group or the placebo group.
Teplizumab or matching placebo will be administered in two courses 6 months apart. Each course of treatment will include daily infusions for 12 days. The total study duration for each participant will be up to 86 weeks.
The primary objective is to determine whether two courses of teplizumab administered 6 months apart slows the loss of β cells and preserves β cell function over 18 months (78 weeks) in children and adolescents 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.
The secondary objectives are to evaluate improvements in key clinical parameters of diabetes management, to determine the safety and tolerability of teplizumab, and to evaluate the pharmacokinetics (PK) and immunogenicity of teplizumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Teplizumab was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days. Each course included: * Day 1: 106 μg/m\^2 * Day 2: 425 μg/m\^2 * Days 3-12: 850 μg/m\^2 Total per course: 9.0 mg/m\^2 The doses of study drug were calculated based on the participant's body surface area (BSA) measured on the first day of each treatment course.
Biological: teplizumab
Placebo was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days. The placebo solution consisted of the same formulation as the study drug but without teplizumab. Placebo was administered in the same dose volume and by the same treatment schedule as the active drug.
Biological: Placebo
Treatment
Control
Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT)
The area under the concentration-time curve (AUC) of C-peptide was measured after a 4-hour mixed meal tolerance test (MMTT) and is a measure of endogenous insulin production and β cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test, i.e., AUC was divided by the last blood sample collection time (240 minutes or the last collection time for 4h MMTT).
Time frame: Baseline to Week 78
Average Daily Exogenous Insulin Use
The average daily insulin use was calculated based on participants who have at least 3 days of insulin use recorded in the dairy for the Week 78 visit.
Time frame: Week 78
Change in Glycated Hemoglobin (HbA1c) Levels (%)
Change in percentage (%) glycated hemoglobin (HbA1c)
Time frame: Baseline to Week 78
Time in Range for Glycemia Control
Time in range (%) for glycemia control was assessed using Continuous Glucose Monitoring (CGM). Time in range was defined as daily average percentage of time a participant's glucose is \>= 70 mg/dL and \<=180 mg/dL. Time in range was calculated based on participants who had at least 3 days of CGM data recorded for Week 78 visit with a range of at least 8 hours on a given day.
Time frame: Week 78
Rate of Clinically Important Hypoglycemic Events
Rate = clinically important hypoglycemic events/patient-year. A clinically important episode was defined as a blood glucose value of \<54 mg/dL (3.0 mmol/L) (i.e., Level 2 Hypoglycemia, International Hypoglycemia Study Group, 2017) or a hypoglycemia event of severe cognitive impairment requiring external assistance (such as seizure, syncope, severe confusion with or without a confirmatory low blood glucose reading) (i.e., Level 3 Hypoglycemia, International Hypoglycemia Study Group 2017). Event rate was calculated for each participant as number of events / total study follow-up time. Total study follow-up time was calculated as (the date of last study contact - the first dose date + 1)/365.25. The summary is based on the data reported post-baseline in the Hypoglycemic Events Electronic Diary (eDiary).
Time frame: During the entire study (from the first dose to the last study contact, up to 78 Weeks)
Number of Participants With Adverse Events of Special Interest (AESIs)
AESIs are defined in the protocol and categories in the statistical analysis plan. Participants with multiple events are counted only once for each preferred term and category.
Time frame: During the entire study (from the first dose to the last study contact, up to 78 Weeks)
Teplizumab Serum Concentrations
PK samples were collected prior to dosing except for Day 9 in Course 1. An additional PK sample was collected 45 minutes after infusion on Day 9 in Course 1. Concentration values below Lower Limit of Quantification (2.50 ng/mL) were set to zero for summary statistics. Course 2 day numbers were set relative to the first day of dosing, regardless of normal or modified dosing schedule.
Time frame: Pre-dose samples collected on Days 1, 4, 9, 12 and 28 for each of the two treatment courses, and one post-dose sample collected on Day 9 during the first treatment course.
Anti-teplizumab Antibody (ADA) Titers After Treatment Courses
Baseline was defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.
Time frame: Baseline through 78 Week
Incidence of Anti-drug Antibodies (ADA) After Treatment Courses
Baseline is defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.
Time frame: From baseline through Week 78
The first participant was enrolled on April 5, 2019, and the last participant was enrolled on November 4, 2021.
| Milestone | Placebo | Teplizumab |
|---|---|---|
| Started | 111 | 217 |
| Completed | 101 | 195 |
| Not completed | 10 | 22 |
| Withdrew: Adverse event | 0 | 5 |
| Withdrew: Withdrawal by subject | 8 | 11 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 5 |
| Withdrew: Personal reasons | 2 | 0 |
The area under the concentration-time curve (AUC) of C-peptide was measured after a 4-hour mixed meal tolerance test (MMTT) and is a measure of endogenous insulin production and β cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test, i.e., AUC was divided by the last blood sample collection time (240 minutes or the last collection time for 4h MMTT).
| pmol/mL | Placebo | Teplizumab |
|---|---|---|
| Intent-to-treat | -0.2112 (-0.2437 to -0.1786) | -0.0859 (-0.1090 to -0.0628) |
| Per Protocol | -0.2185 (-0.2501 to -0.1869) | -0.0800 (-0.1030 to -0.0570) |
The average daily insulin use was calculated based on participants who have at least 3 days of insulin use recorded in the dairy for the Week 78 visit.
| Units/kg/day | Placebo | Teplizumab |
|---|---|---|
| Intent-to-treat | 0.593 (0.470 to 0.716) | 0.463 (0.363 to 0.562) |
| Per Protocol | 0.613 (0.538 to 0.687) | 0.446 (0.390 to 0.502) |
Change in percentage (%) glycated hemoglobin (HbA1c)
| Percentage of glycated hemoglobin | Placebo | Teplizumab |
|---|---|---|
| Intent-to-treat | -1.89 (-2.16 to -1.62) | -1.98 (-2.17 to -1.78) |
| Per Protocol | -1.94 (-2.21 to -1.67) | -2.07 (-2.27 to -1.87) |
Time in range (%) for glycemia control was assessed using Continuous Glucose Monitoring (CGM). Time in range was defined as daily average percentage of time a participant's glucose is \>= 70 mg/dL and \<=180 mg/dL. Time in range was calculated based on participants who had at least 3 days of CGM data recorded for Week 78 visit with a range of at least 8 hours on a given day.
| Percentage of time in range | Placebo | Teplizumab |
|---|---|---|
| Intent-to-treat | 62.65 (57.38 to 67.92) | 67.36 (63.70 to 71.03) |
| Per Protocol | 61.44 (56.50 to 66.38) | 67.61 (64.09 to 71.14) |
Rate = clinically important hypoglycemic events/patient-year. A clinically important episode was defined as a blood glucose value of \<54 mg/dL (3.0 mmol/L) (i.e., Level 2 Hypoglycemia, International Hypoglycemia Study Group, 2017) or a hypoglycemia event of severe cognitive impairment requiring external assistance (such as seizure, syncope, severe confusion with or without a confirmatory low blood glucose reading) (i.e., Level 3 Hypoglycemia, International Hypoglycemia Study Group 2017). Event rate was calculated for each participant as number of events / total study follow-up time. Total study follow-up time was calculated as (the date of last study contact - the first dose date + 1)/365.25. The summary is based on the data reported post-baseline in the Hypoglycemic Events Electronic Diary (eDiary).
| Events/patient-year | Placebo | Teplizumab |
|---|---|---|
| Intent-to-treat | 4.24 (3.06 to 5.89) | 4.68 (3.70 to 5.91) |
| Per protocol | 4.63 (3.31 to 6.49) | 5.04 (3.94 to 6.44) |
AESIs are defined in the protocol and categories in the statistical analysis plan. Participants with multiple events are counted only once for each preferred term and category.
| Participants | Placebo | Teplizumab |
|---|---|---|
| Treatment-emergent AESI | 24 | 63 |
| Participants with at least one >= grade 3 infection | 2 | 1 |
| Participants with at least one acute mononucleosis-like illness | 3 | 17 |
| Participants with at least one lymphoma or other malignancy, including benign tumors | 1 | 2 |
| Participants with at least one instance of severe hypoglycemic event | 18 | 29 |
| Participants with at least one >=grade 3 liver function abnormality | 0 | 8 |
| Participants with at least one >= grade 3 thrombocytopenia | 0 | 0 |
| Participants with at least one >= grade 3 neutropenia | 0 | 7 |
| Participants with at least one >= grade 4 allergic/hypersensitivity reaction | 0 | 0 |
| Participants with at least one >= grade 3 rash | 0 | 4 |
PK samples were collected prior to dosing except for Day 9 in Course 1. An additional PK sample was collected 45 minutes after infusion on Day 9 in Course 1. Concentration values below Lower Limit of Quantification (2.50 ng/mL) were set to zero for summary statistics. Course 2 day numbers were set relative to the first day of dosing, regardless of normal or modified dosing schedule.
| ng/mL | Teplizumab |
|---|---|
| Course 1, Day 1 | 7.4271 ± 628.114 |
| Course 1, Day 4 | 70.4769 ± 50.767 |
| Course 1, Day 9 | 250.3928 ± 44.677 |
| Course 1, Day 9 post-dose | 636.4390 ± 33.171 |
| Course 1, Day 12 | 305.6569 ± 47.048 |
| Course 1, Day 28 | 25.0317 ± 79.953 |
| Course 2, Day 1 | 5.5433 ± 522.457 |
| Course 2, Day 4 | 82.0166 ± 50.333 |
| Course 2, Day 9 | 145.9498 ± 75.737 |
| Course 2, Day 12 | 108.2988 ± 107.776 |
| Course 2, Day 28 | 13.2159 ± 181.421 |
Baseline was defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.
| Titer | Teplizumab |
|---|---|
| Baseline | 65.81 ± 182.3 |
| Week 2 | 177.22 ± 278.2 |
| Week 4 | 817.08 ± 275.0 |
| Week 8 | 1040.58 ± 239.1 |
| Week 26 Day 182 | 834.86 ± 226.1 |
| Week 26 Day 187 | 807.26 ± 681.6 |
| Week 27 | 9257.15 ± 222.3 |
| Week 30 | 9985.29 ± 218.7 |
| Week 34 | 7326.91 ± 237.0 |
| Week 39 | 3701.64 ± 202.8 |
| Week 52 Day 364 | 1398.22 ± 240.1 |
| Week 52 Day 369 | 308.80 ± 207.5 |
| Week 53 | 8043.22 ± 165.7 |
| Week 56 | 14221.44 ± 241.8 |
| Week 60 | 9040.49 ± 299.4 |
| Week 65 | 996.15 ± 484.4 |
| Week 78 | 672.13 ± 332.4 |
Baseline is defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.
| Participants | Teplizumab |
|---|---|
| Baseline — Positive | 15 |
| Baseline — Negative | 200 |
| Week 2 — Positive | 182 |
| Week 2 — Negative | 25 |
| Week 4 — Positive | 178 |
| Week 4 — Negative | 26 |
| Week 8 — Positive | 175 |
| Week 8 — Negative | 31 |
| Week 26 Day 182 — Positive | 139 |
| Week 26 Day 182 — Negative | 53 |
| Week 26 Day 187 — Positive | 130 |
| Week 26 Day 187 — Negative | 40 |
| Week 27 — Positive | 167 |
| Week 27 — Negative | 8 |
| Week 30 — Positive | 169 |
| Week 30 — Negative | 7 |
| Week 34 — Positive | 163 |
| Week 34 — Negative | 13 |
| Week 39 — Positive | 170 |
| Week 39 — Negative | 22 |
| Week 52 Day 364 — Positive | 155 |
| Week 52 Day 364 — Negative | 37 |
| Week 52 Day 369 — Positive | 11 |
| Week 52 Day 369 — Negative | 4 |
| Week 53 — Positive | 15 |
| Week 53 — Negative | 1 |
| Week 56 — Positive | 18 |
| Week 56 — Negative | 1 |
| Week 60 — Positive | 17 |
| Week 60 — Negative | 1 |
| Week 65 — Positive | 153 |
| Week 65 — Negative | 38 |
| Week 78 — Positive | 146 |
| Week 78 — Negative | 45 |
Collected over Treatment-emergent adverse events = from the first dose of study drug administration through the end of the study, up to 78 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/111 (0%) | 6/111 (5.4%) | 88/111 (79.3%) |
| Teplizumab | 0/217 (0%) | 12/217 (5.5%) | 212/217 (97.7%) |
| Event | Placebo | Teplizumab |
|---|---|---|
| GastroenteritisInfections and infestations | 2/111 | 0/217 |
| Cytokine release syndromeImmune system disorders | 0/111 | 3/217 |
| Suicidal ideationPsychiatric disorders | 0/111 | 2/217 |
| SyncopeNervous system disorders | 1/111 | 0/217 |
| ConstipationGastrointestinal disorders | 1/111 | 0/217 |
| AnxietyPsychiatric disorders | 1/111 | 0/217 |
| Device related bacteraemiaInfections and infestations | 1/111 | 0/217 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/111 | 1/217 |
| ConcussionInjury, poisoning and procedural complications | 0/111 | 1/217 |
| PalpitationCardiac disorders | 0/111 | 1/217 |
| Event | Placebo | Teplizumab |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 81/111 | 151/217 |
| HeadacheNervous system disorders | 21/111 | 94/217 |
| NauseaGastrointestinal disorders | 21/111 | 92/217 |
| RashSkin and subcutaneous tissue disorders | 5/111 | 86/217 |
| Lymphocyte count decreasedInvestigations | 5/111 | 73/217 |
| VomitingGastrointestinal disorders | 15/111 | 68/217 |
| PyrexiaGeneral disorders | 11/111 | 53/217 |
| White blood cell count decreasedInvestigations | 6/111 | 53/217 |
| COVID-19Infections and infestations | 26/111 | 49/217 |
| LymphopeniaBlood and lymphatic system disorders | 0/111 | 50/217 |
Intent-to-treat population
| Age, Categorical(Participants) | Placebo | Teplizumab | Total |
|---|---|---|---|
| <=18 years | 111 | 217 | 328 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | Teplizumab | Total |
|---|---|---|---|
| Mean | 12.3 ± 2.55 | 12.0 ± 2.53 | 12.1 ± 2.54 |
| Sex: Female, Male(Participants) | Placebo | Teplizumab | Total |
|---|---|---|---|
| Female | 42 | 98 | 140 |
| Male | 69 | 119 | 188 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Teplizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 14 | 18 |
| Not Hispanic or Latino | 101 | 193 | 294 |
| Unknown or Not Reported | 6 | 10 | 16 |
| Race/Ethnicity, Customized(Participants) | Placebo | Teplizumab | Total |
|---|---|---|---|
| White | 94 | 189 | 283 |
| Black or African American | 6 | 5 | 11 |
| Asian | 3 | 4 | 7 |
| American Indian or Alaskan Native | 0 | 1 | 1 |
| Native Hawiian or Other Pacific Islander | 1 | 0 | 1 |
| Multiple | 0 | 6 | 6 |
| Other | 1 | 4 | 5 |
| Not reported | 6 | 8 | 14 |
| Region of Enrollment(participants) | Placebo | Teplizumab | Total |
|---|---|---|---|
| Canada | 7 | 13 | 20 |
| Belgium | 4 | 1 | 5 |
| United States | 56 | 126 | 182 |
| Czechia | 10 | 17 | 27 |
| Poland | 15 | 33 | 48 |
| United Kingdom | 6 | 6 | 12 |
| France | 5 | 9 | 14 |
| Germany | 8 | 12 | 20 |
| Peak C-peptide at screening(Participants) | Placebo | Teplizumab | Total |
|---|---|---|---|
| 0.2 - 0.7 pmol/mL | 47 | 91 | 138 |
| >0.7 pmol/mL | 64 | 126 | 190 |
| Age group at randomization(Participants) | Placebo | Teplizumab | Total |
|---|---|---|---|
| 8 - 12 years | 62 | 120 | 182 |
| >12 - 17 years | 49 | 97 | 146 |
17 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient levels data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After drug approval
Access criteria: Qualified researchers
Data sharing details ↗ · vivli.org
Ran from Apr 2019 to primary completion in May 2023, 48 months.
Results were first posted in Apr 2024, 11 months after primary completion.
Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 48 months is above that.
Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teplizumab